Merck Targets $70 Billion Revenue by mid-2030s to Counter Keytruda Patent Cliff
Merck (MSD) announced a revenue target of $70 billion by the mid-2030s, driven by new growth opportunities and a diversified pipeline to offset Keytruda's patent expiration.
$70 billion—that's the massive revenue milestone Merck plans to hit by the mid-2030s. As reported by Reuters, the pharmaceutical giant is betting on new growth opportunities to diversify its portfolio and sustain momentum as it faces the eventual loss of exclusivity for its top-selling drug.
Strategic Roadmap for Merck 70 Billion Revenue Target 2035
Merck's ambitious outlook comes at a critical juncture. The company's blockbuster immunotherapy, Keytruda, currently generates a significant portion of its total sales but will begin losing patent protection later this decade. To bridge the gap, Merck is aggressively expanding into oncology, immunology, and vaccines.
- Cardiovascular Growth: Expected to contribute over $15 billion in revenue by the early 2030s
- Pipeline Expansion: Accelerating R&D in ADC (Antibody-Drug Conjugates) and next-gen vaccines.
- M&A Activity: Continued focus on acquiring biotech firms with high-potential late-stage assets.
This content is AI-generated based on source articles. While we strive for accuracy, errors may occur. We recommend verifying with the original source.
Related Articles
Genmab has discontinued the development of an experimental cancer therapy. Reuters reports a shift in focus to more promising assets within the Danish biotech's pipeline.
Nvidia agrees to acquire Groq assets for a record-breaking $20 billion as the S&P 500 continues its year-end rally. Leather goods prices surge 22% amid tariff pressures.
Big Pharma faces a $171B revenue cliff. Their solution? Chinese biotech. Our analysis unpacks the high-stakes clash between economic need and geopolitical risk.
Grayscale has filed for a spot BNB ETF following the successful Fermi hard fork upgrade. Learn how these developments could impact BNB's institutional adoption.
Genmab has discontinued the development of an experimental cancer therapy. Reuters reports a shift in focus to more promising assets within the Danish biotech's pipeline.
Nvidia agrees to acquire Groq assets for a record-breaking $20 billion as the S&P 500 continues its year-end rally. Leather goods prices surge 22% amid tariff pressures.
Big Pharma faces a $171B revenue cliff. Their solution? Chinese biotech. Our analysis unpacks the high-stakes clash between economic need and geopolitical risk.
Grayscale has filed for a spot BNB ETF following the successful Fermi hard fork upgrade. Learn how these developments could impact BNB's institutional adoption.